Regular use of analgesics is a risk factor for renal cell carcinoma
Regular use of analgesics is a risk factor for renal cell carcinoma
复制标题
DOI：
10.1038/sj.bjc.6690728
复制
发表时间：
1999-10-01
影响因子：
8.8
通讯作者：
Yu, MC
中科院分区：
文献类型：
--
作者：
Gago-Dominguez, M;Yuan, JM;Yu, MC
非那西丁类镇痛药与肾盂癌和肾细胞癌（RCC）的发生有关;非那西丁类镇痛药与肾癌之间的关系尚不清楚，尽管实验室证据表明这些药物具有致癌潜力。在加州的洛杉矶进行了一项基于人群的病例对照研究，包括1204例年龄在25-74岁的非亚裔RCC患者和相同数量的性别、年龄和种族匹配的社区对照，以根据主要制剂类别调查持续使用镇痛剂与RCC风险之间的关系。通过面对面访谈收集了有关病史和用药史以及其他生活方式因素的详细信息。定期使用止痛药是男性和女性RCC的一个重要风险因素（男女合并的比值比（OR）= 1.6，95%置信区间（CI）= 1.4-1.9）。所有四类主要镇痛药（阿司匹林、阿司匹林以外的非甾体类抗炎药、对乙酰氨基酚和非那西丁）的风险均升高。在每一类镇痛剂中，随着暴露水平的增加，风险在统计学上显著增加。尽管主要制剂类别存在一些微小的变异性，但一般而言，最高暴露类别的个体相对于非或不定期使用镇痛剂的个体显示出约2.5倍的风险增加。每天服用一次常规强度（即325 mg）阿司匹林或更少阿司匹林预防心血管疾病的受试者患RCC的风险并未增加（OR = 0.9，95% CI = 0.0-1.4）。(C)1999年癌症研究运动。
Phenacetin-based analgesics have been linked to the development of renal pelvis cancer and renal cell carcinoma (RCC); The relationship between non-phenacetin types of analgesics and kidney cancer is less clear, although laboratory evidence suggests that these drugs possess carcinogenic potential. A population-based case-control study involving 1204 non-Asian RCC patients aged 25-74 and an equal number of sex-, age- and race-matched neighbourhood controls was conducted in Los Angeles, California, to investigate the relationship between sustained use of analgesics and risk of RCC according to major formulation categories. Detailed information on medical and medication histories, and other lifestyle factors was collected through in-person interviews. Regular use of analgesics was a significant risk factor for RCC in both men and women (odds ratio (OR) = 1.6, 95% confidence interval (CI) = 1.4-1.9 for both sexes combined). Risks were elevated across all four major classes of analgesics (aspirin, non-steroidal anti-inflammatory agents other than aspirin, acetaminophen and phenacetin). Within each class of analgesics, there was statistically significant increasing risk with increasing level of exposure. Although there was some minor variability by major class of formulation, in general individuals in the highest exposure categories exhibited approximately 2.5-fold increase in risk relative to non- or irregular users of analgesics. Subjects who took one regular-strength (i.e. 325 mg) aspirin a day or less for cardiovascular disease prevention were not at an increased risk of RCC (OR = 0.9, 95% CI = 0.0-1.4). (C) 1999 Cancer Research Campaign.